Cannabis Appetite Stimulation Study Launched
Applied Cannabis Research (ACR), a division of Southern Cannabis Holdings (SCH), has launched a new Observational Study to assess the impact of THC-based medications for sufferers of Cachexia and is pleased to announce that the medication and TGA SAS-B application process will be fully funded until 30th April 2020 on compassionate grounds.
Key Highlights:
Applied Cannabis Research (ACR) is conducting a 6-month study investigating the impact of THC-dominant medication on Cachexia.
Participant recruitment will be over a 10 week period from 17th Feb - 24th April 2020
Medications and one-time TGA SAS B application costs are funded prior to April 30th 2020
Medications after April 30th 2020 will be prescribed and dispensed at normal retail prices
GP consultation fees are applicable throughout the study
Study will be conducted by SCH division CA Clinics.
Further study is important to determine whether patients with cachectic conditions such as cancer-related anorexia-cachexia syndrome (CACS) see an improvement in appetite and quality of life using THC-dominant medical treatment.
ACR is working together with CA Clinics, that will coordinate the recruitment and assessment of suitable patients. After the 10 week recruitment period, patients will return to a normal prescription scenario with the patient meeting the cost of their ongoing prescription needs. This will allow us to further assess the continuity of cannabis use in a ‘normal’ environment . Doctor consultation fees will be applicable during this study.
If you are a doctor and have patients who you feel may be suitable, or wish to discuss the study further, please contact CA Clinics on 1300 991 477 or email us at info@caclinics.com.au. Alternatively, contact Applied Cannabis Research to discuss this study or any one of a range of other studies we are currently conducting.
Dr Mark Hardy, Medical Advisory Board Member at CA Clinics, commented: “On top of the obvious informational benefits of the study, this compassionate study offers an excellent starting point for patients who aren't contraindicated for THC to use a medication for no cost for a period of time, while being assessed and monitored in a safe setting.”
Dr John Barlow (PhD), Research Lead at Applied Cannabis Research commented “This study will be one of the first clinical opportunities in the world to assess and collect data that compares long-term safety of THC-dominant medications against currently available treatments. Australia is ideally positioned to undertake this type of research because of its world class healthcare framework and pharmaceutical quality standards.”
About Applied Cannabis Research
Applied Cannabis Research is a specialist contract research organisation providing medicinal cannabis companies with services to assess the therapeutic efficacy of their products. Applied Cannabis Research undertake a range of ethical observational studies nationally into various conditions where patients have exhausted conventional therapies. For more information: info@appliedcannabisresearch.com.au or (+61) 2 8294 6406 @CannabisApplied
CA Clinics is the first and largest network of medicinal cannabis clinics in Australia, helping patients with chronic conditions such as chronic pain to access better health outcomes and improve their quality of life. For more information: www.cannabisaccessclinics.com.au or info@caclinics.com.au @caccessclinics